In a 40‑year‑old woman with a red rash confined to the cheeks and nose, what is the most likely diagnosis and recommended treatment?

Red Rash on Cheeks and Nose in a 40-Year-Old Female

The most likely diagnosis is rosacea, and first-line treatment should be topical metronidazole 0.75% or azelaic acid 15% gel, combined with general skincare measures including gentle cleansers, moisturizers, and broad-spectrum sunscreen. 1, 2

Most Likely Diagnosis: Rosacea

A red rash confined to the cheeks and nose in a 40-year-old woman is classic for rosacea, particularly the erythematotelangiectatic or papulopustular phenotypes. This demographic (middle-aged women, fair-skinned) represents the typical rosacea patient population 3, 2. The centrofacial distribution—affecting forehead, nose, chin, and cheeks—is pathognomonic for rosacea 4.

Key Clinical Features to Confirm:

• Persistent or transient erythema (flushing episodes lasting <5 minutes)
• Telangiectasia (visible blood vessels)
• Inflammatory papules/pustules (if present)
• Absence of comedones (distinguishes from acne)
• Triggers: hot beverages, spicy foods, alcohol, sun exposure, emotional stress 2

Treatment Algorithm

Step 1: General Skincare (All Patients)

• Avoid triggers (hot water, harsh cleansers, excessive sun exposure) 3
• Use gentle, alcohol-free cleansers and moisturizers with urea 5-10% 3
• Apply broad-spectrum sunscreen SPF ≥30 daily, reapply every 2 hours when outdoors 3

Step 2: Phenotype-Based First-Line Topical Therapy

For persistent erythema without inflammatory lesions:

• Brimonidine gel 0.33% once daily (vasoconstrictor, reduces redness within 30 minutes to 6 hours) 3
• Alternative: Oxymetazoline HCl 1% cream once daily 3

For inflammatory papules/pustules (with or without erythema):

• Metronidazole 0.75% gel twice daily OR 1% gel once daily 3, 2
• Azelaic acid 15% gel twice daily 3, 2
• Ivermectin 1% cream once daily (superior to metronidazole in head-to-head trials: 83% vs 73.7% lesion reduction, longer time to relapse 115 vs 85 days) 3

The 2024 rosacea treatment landscape review confirms these as established first-line agents 3. Ivermectin 1% cream demonstrated superior efficacy compared to metronidazole 0.75% in direct comparison studies and is now considered more effective based on network meta-analysis 3.

Step 3: Reassess at 2-4 Weeks

If inadequate response:

• Add or switch to another first-line topical agent
• Consider combination therapy: anti-inflammatory topical (ivermectin, azelaic acid, metronidazole) PLUS vasoconstrictor (brimonidine or oxymetazoline) for additive benefits 3
• Add oral doxycycline 40 mg once daily (modified-release, anti-inflammatory dose) for moderate-to-severe papulopustular disease 3, 2

Step 4: Systemic Therapy for Moderate-to-Severe Disease

Oral doxycycline 40 mg (modified-release) once daily:

• Anti-inflammatory properties at sub-antimicrobial dose 3
• Demonstrated 60% reduction in inflammatory lesions at 16 weeks 3
• Continue for at least 6 weeks, taper as tolerated 5

Alternative systemic options:

• Oral tetracyclines (doxycycline 100 mg twice daily, minocycline 50-100 mg twice daily) 5, 6
• Low-dose isotretinoin (20-30 mg/day) for resistant cases 5

Step 5: Maintenance Therapy

• Continue topical therapy long-term to prevent relapse 3
• Ivermectin 1% showed more durable response (115 days to relapse vs 85 days with metronidazole) 3
• Taper oral antibiotics once control achieved; restart if relapse occurs 1

Newer Treatment Options

Encapsulated benzoyl peroxide 5% (E-BPO) cream once daily:

• FDA-approved 2022 for inflammatory rosacea lesions 3
• Microencapsulation technology reduces irritation while maintaining efficacy 3
• Rapid onset (improvement by week 2), sustained results up to 52 weeks 3
• Consider for patients who cannot tolerate traditional topicals

Minocycline 1.5% foam once daily:

• FDA-approved 2020 3
• 64% lesion reduction at 12 weeks, low adverse effects (1.5%) 3

Important Caveats

Avoid Common Pitfalls:

• Do not use topical corticosteroids long-term—may worsen rosacea and cause steroid-induced rosacea 6
• Tetracyclines contraindicated in pregnancy and children <8 years (tooth staining) 6
• Azithromycin warning: FDA alert for cardiovascular deaths, particularly in patients with baseline cardiovascular disease 6
• Brimonidine paradoxical erythema: 10-20% of patients may experience rebound redness 3

When to Refer:

• Ocular symptoms (burning, grittiness, redness): refer to ophthalmology for lid hygiene, artificial tears, topical cyclosporine, or systemic antibiotics 6, 1
• Phymatous changes (rhinophyma, thickened skin): refer for laser ablation or surgical treatment 1, 2
• Telangiectasia: refer for pulsed dye laser or intense pulsed light therapy 7, 2

Alternative Diagnoses to Consider

If presentation atypical or treatment fails:

• Systemic lupus erythematosus (malar rash spares nasolabial folds, unlike rosacea)
• Seborrheic dermatitis (greasy scales, involves nasolabial folds)
• Contact dermatitis (history of new skincare products)
• Drug-induced photosensitivity (medication history)

The phenotype-based approach endorsed by the 2017 Global Rosacea Consensus (ROSCO) panel allows simultaneous treatment of multiple features with multiple agents, providing more personalized and effective management than the older subtype-based classification 1.